Published by Josh White on 15th March 2024
(Sharecast News) - Biotechnology company Sareum announced on Friday that the European Patent Office had issued a notice of allowance for a patent concerning SDC‐1801, its primary TYK2/JAK1 kinase inhibitor currently undergoing clinical trials in Australia.
URL: http://www.digitallook.com/dl/news/story/34159116/...